New drug APSTZD aims to improve sleep in insomnia patients

NCT ID NCT07420816

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase II trial tests a new drug called APSTZD for people with chronic insomnia. About 222 adults aged 18-64 will receive either APSTZD, an active comparator (Stilnox CR), or a placebo. The main goal is to see if APSTZD reduces time awake after falling asleep, measured by overnight sleep studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

APSTZD

What this could lead to

If successful, APSTZD could offer a new treatment option for people with chronic insomnia, improving sleep quality.

What could go wrong

This is an early Phase II trial with a small number of participants. The drug may not prove more effective than existing treatments or placebo, and side effects are still being evaluated.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INSOMNIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

insomnia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UNIFAG - Casa Nossa Senhora da PAZ -ASF

    Bragança Paulista, São Paulo, 12916-900, Brazil

    Contact Phone: •••-•••-•••• Email: •••••@•••••